UK's NICE Endorses Accord's Relugolix for Prostate Cancer

The UK National Institute for Health and Care Excellence (NICE) has given its endorsement to Accord's Relugolix (Orgovyx) as a treatment for advanced hormone-sensitive prostate cancer. This marks a significant milestone as Relugolix becomes the first oral androgen deprivation therapy (ADT) recommended by NICE, potentially benefiting around 40,000 patients.

Traditional hormone treatments for prostate cancer are typically administered through injections. In contrast, Relugolix is available in an oral tablet form, allowing patients the convenience of taking their medication at home. Prostate cancer cells rely on androgen hormones like testosterone to grow. ADT aims to reduce the levels of these hormones, either by medication or surgical intervention, to help inhibit the growth of prostate cancer cells.

Relugolix works by blocking the production of testosterone in the testes, thereby significantly lowering its levels. This oral medication could offer a more convenient and flexible treatment option compared to injectable therapies, reducing the need for frequent travel and work absences for patients.

ADT has been associated with an increased risk of cardiovascular problems, such as heart attacks and heart failure. Clinical trials have shown that Relugolix can maintain lower testosterone levels more effectively compared to leuprolide, a commonly used injectable ADT. This is crucial for stopping the growth of prostate cancer. Additionally, Relugolix has been found to reduce the risk of serious cardiovascular events.

An indirect comparison of treatments has suggested that Relugolix is as effective as other ADTs. It offers a more user-friendly and flexible treatment option compared to injectable therapies, which can help patients avoid travel and minimize time away from their daily routines and work commitments.

Helen Knight, the director of medicines evaluation at NICE, emphasized the importance of this recommendation. She stated, "We are continuing to focus on what matters most to people by recommending this innovative and effective treatment that can make a positive difference to people with advanced prostate cancer. Relugolix provides a convenient and flexible treatment option compared with therapies that need to be injected, helping people to avoid travel and time off work, and the evidence shows it can improve people’s quality of life."

In summary, the endorsement of Relugolix by NICE as an oral treatment for advanced hormone-sensitive prostate cancer offers a promising new option for patients. With its ease of use and potential to lower cardiovascular risks, Relugolix stands out as a significant advancement in the treatment landscape for prostate cancer. The approval underscores NICE's commitment to introducing innovative treatments that align with the needs and preferences of patients.